[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-360512-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-360512-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","shld2-loss-is-a-synthetic-vulnerability-to-pol-inhibition-combined-with-radiotherapy-paper","SHLD2 loss is a synthetic vulnerability to Polθ inhibition combined with radiotherapy - Paper","","Radiotherapy is widely used for solid tumors but its tumor selectivity is limited, motivating development of drugs that radiosensitize cancer cells while sparing normal tissue. DNA polymerase theta (Polθ) inhibition has shown strong single-agent radiosensitization potential, yet actionable biomarkers predicting radiosensitization are lacking. Profiling 54 cancer cell lines and performing a CRISPR knockout screen identified SHLD2 loss in the TP53BP1/Shieldin pathway as a vulnerability that enhances combined Polθ inhibition and radiotherapy, including in prostate cancers with frequent PTEN loss, supporting a model of radiation-driven Polθ dependency.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/shld2-loss-is-a-synthetic-vulnerability-to-pol-inhibition-combined-with-radiotherapy-paper/360512/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/shld2-loss-is-a-synthetic-vulnerability-to-pol-inhibition-combined-with-radiotherapy-paper/360512.png","ImageObject",300,407,{"name":42,"@type":43},"Grenda","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-05","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is radiotherapy often combined with radiosensitizing drugs?","Question",{"text":63,"@type":64},"Radiotherapy can damage normal tissues, and tumor control benefits are offset by side effects. Radiosensitizers aim to increase ionizing-radiation damage preferentially in tumor cells.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What role does Polθ play in DNA repair relevant to this study?",{"text":68,"@type":64},"Polθ is a DNA polymerase involved in microhomology-mediated end joining (MMEJ), an error-prone repair pathway that repairs DNA double-strand breaks (DSBs) and leaves characteristic genomic scars.",{"name":70,"@type":61,"acceptedAnswer":71},"How does SHLD2 loss affect radiosensitization when combined with Polθ inhibition and RT?",{"text":72,"@type":64},"The study identifies SHLD2 loss (in the TP53BP1/Shieldin pathway component) as a vulnerability that enhances radiosensitization from Polθ inhibition combined with radiotherapy. This increased sensitivity to RT and radiosensitizing effect occurs independently of PTEN status and without requiring HR deficiency.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},360512,1790179172,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},7971474921005,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","CANCER  \nSHLD2 loss is a synthetic vulnerability to Polθ inhibition combined with radiotherapy  \nGonzalo Rodriguez-Berriguete1†, PurusothaThambiayah1†, Alessandro Cicconi2, Nicole Machado1, Celia Gotorbe1, David Nderitu1, Wei-Chen Cheng1, Gerissa Fowler1,  \nMarie Laure Boursier2, Aurora Cerutti2, Vera Grinkevich2, Bethany Rebekah Hill2, Katjuša Koler2, Sophie Alice Langdon2, Jayesh B. Majithiya2, Suraj Menon2, Shaun Moore2, Joana Neves2, Natalie M. Palmer-Deverill2, Eeson Rajendra2, Marina Roy-Luzarraga2, AsmitaThapa2,  \nRobert A. Heald2, Graeme C. M. Smith2, Helen M. R. Robinson2,  \nMarco Ranzani2*, Geoff S. Higgins1*  \nInhibition of DNA polymerase theta (Polθ), an essential enzyme for repairing DNA double-strand breaks (DSBs) via microhomology-mediated end joining (MMEJ), has proven to be an exquisitely effective monotherapy in HRdeficient tumor models. In addition, Polθ inhibition (Polθi) can induce tumor-selective radiosensitization, but unlike its monotherapy use, no clinically actionable biomarkers have yet been identified to predict this effect. Here, we profiled 54 cancer cell lines and found that Polθi induces substantial radiosensitization in most models, although with marked variability not explained by indicators of Polθ activity. To pinpoint molecular determinants of radiosensitization by Polθi, we performed a CRISPR knockout screen which revealed loss oftheTP53BP1/Shieldin pathway componentSHLD2 (FAM35A) as a vulnerability to Polθi combined with RT. We found that SHLD2 is deleted in a subset of human prostate cancers, frequently alongside PTEN loss, an adverse prognostic factor. We demonstrated that SHLD2 loss not only increases sensitivity to RT alone, as reported previously, but also enhances the radiosensitizing effect of Polθi, independently of PTEN status and without requiring HR deficiency. Moreover, our findings support a model in which SHLD2 deficiency increases Polθ dependence following RT, with Polθ activity limiting DSB accumulation and chromosomal instability, via a compensatory mechanism independent of canonical MRE11/CtIP-mediated DNA end resection. In summary, we found that SHLD2 loss is a collateral vulnerability that can be exploited through combined treatment with Polθi and RT.  \ncopyright © 2026 the Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. no claim to original U.S.  \nGovernment Works. distributed under a creative commons Attribution license 4.0 (cc BY) .  \nINTRODUCTION  \nRadiotherapy (RT) plays a key role in the treatment of many solid tumors. When given with curative intent, RT is often combined with conventional chemotherapies to sensitize tumors to ionizing radiation. However, these effects are not tumor specific, and the benefit of these treatments in improving tumor control is offset by side effects caused by increased damage to surrounding normal tissues ( 1) . Therefore, there is major interest in combining RT with drugs that exert a radiosensitizing effect selectively in tumor cells. In this regard, we have previously reported that pharmacological inhibition of Polθ is an effective and safe approach for tumor-selective radiosensitization in preclinical models (2) .  \nPolθ (encoded by the POLQ gene) is a type A DNA polymerase that also contains a helicase domain and plays a critical role in therepair of DNA double-strand breaks (DSBs) by microhomologymediated end joining (MMEJ), an error prone repair pathway (3) . According to current models, during MMEJ repair, MRE11/CtIPmediated initiation of 5 ′ → 3 ′ resection at the DSB generates 3 ′ overhangs, exposing short, complementary microhomologies (4) . The helicase domain of Polθ then facilitates the annealing of these microhomologies, and its polymerase domain fills in and seals the resulting gaps (5, 6) . This error-prone repair leaves characteristic genomic “scars” at the DSB site, consisting of short deletions flanked  \n1department of Oncology, University of Oxford, Oxford, ","cbCaihc4BlEXriDh","https://ap.wps.com/l/cbCaihc4BlEXriDh","pdf",3332560,15,"English","# Introduction\n## DNA polymerase theta (Polθ) biology and repair mechanism\n## Rationale for combining Polθ inhibition with radiotherapy\n# Results\n## Polθi-induced radiosensitization varies across cancer cell lines","[{\"question\":\"Why is radiotherapy often combined with radiosensitizing drugs?\",\"answer\":\"Radiotherapy can damage normal tissues, and tumor control benefits are offset by side effects. Radiosensitizers aim to increase ionizing-radiation damage preferentially in tumor cells.\"},{\"question\":\"What role does Polθ play in DNA repair relevant to this study?\",\"answer\":\"Polθ is a DNA polymerase involved in microhomology-mediated end joining (MMEJ), an error-prone repair pathway that repairs DNA double-strand breaks (DSBs) and leaves characteristic genomic scars.\"},{\"question\":\"How does SHLD2 loss affect radiosensitization when combined with Polθ inhibition and RT?\",\"answer\":\"The study identifies SHLD2 loss (in the TP53BP1/Shieldin pathway component) as a vulnerability that enhances radiosensitization from Polθ inhibition combined with radiotherapy. This increased sensitivity to RT and radiosensitizing effect occurs independently of PTEN status and without requiring HR deficiency.\"}]","SHLD2 loss is a synthetic vulnerability to Polθ inhibition combined with radiotherapy - Paper | PDF",1790140334,38,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9aa0b09a9e0cf9a7fc8657e9cadfc12a.webp",983,1250,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4f322083489760405c0c5d0ecb1ac6b4.webp",982,1249,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/309d4f392750f160a951ffc34cfc552e.webp",981,1248,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/869a9964249a263b74f7b7bc604a1771.webp",980,1247]